✦ LIBER ✦

Mitoxantrone/high-dose ara-c and recombinant human gm-csf in the treatment of refractory non-hodgkin's lymphoma a pilot study

✍ Scribed by Anthony D. Ho; Francesco Del Valle; Marianne Engelhard; Wolfgang Hiddemann; Heide Rückle; GüNter Schlimok; Rainer Haas; Ekhard Thiel; Reinhard Andreesen; Walter Fiedler; Jürgen Frisch; Gregor Schulz; Werner Hunstein

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 741 KB
Volume: 66
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19900801)66:3<423::aid-cncr2820660304>3.0.co;2-v

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of refractory Hodgkin's diseas

Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin study group

✍ Wolfgang Hiddemann; Norbert Schmitz; Michael Pfreundschuh; Karl-Heinz Pflüger; J 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 570 KB

A phase I trial to assess the value of r

A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (r-MetHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL)

✍ G. M. Smith; J. A. Child; M. H. Cullen; N. P. Bailey; C. M. Woodruffe; J. Fletch 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

In a multi-centre phase I study we investigated the possibility of reducing the interval between courses of standard CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m', vincristine 2 mgs day 1, and prednisolone 40mglm' days 1-8) from 21 days to 15 days and then 10 days using granulocyte colony s